RBGLY Investors Have Opportunity to Lead Reckitt Benckiser Group PLC Securities Fraud Lawsuit

Published: Tuesday, June 24, 2025 at 12:20 am

Investors in Reckitt Benckiser Group PLC (RBGLY) Face Securities Fraud Lawsuit

NEW YORK - Investors who purchased American Depositary Shares (ADSs) of Reckitt Benckiser Group PLC (RBGLY) between January 13, 2021, and July 28, 2024, are being notified of a securities fraud lawsuit. The Rosen Law Firm, a global investor rights law firm, is representing investors in this class action.

The lawsuit alleges that during the specified "Class Period," the defendants failed to adequately inform investors and consumers about potential risks associated with Reckitt's cow's milk-based formula, Enfamil. Specifically, the suit claims that preterm infants consuming Enfamil faced an increased risk of developing necrotizing enterocolitis (NEC). The lawsuit further alleges that the defendants did not disclose the potential impact of these risks on Enfamil sales and Reckitt's exposure to legal claims. As a result, the lawsuit claims that positive statements made about Reckitt's business, operations, and prospects were misleading, leading to investor damages.

Investors who purchased RBGLY ADSs during the Class Period may be entitled to compensation through a contingency fee arrangement, meaning they would not pay any out-of-pocket fees or costs. The deadline for investors to move the Court to serve as lead plaintiff is August 4, 2025. The lead plaintiff will represent other class members in directing the litigation. Investors can join the class action by visiting the Rosen Law Firm's website or contacting them via phone or email.

The Rosen Law Firm emphasizes its experience in securities class actions, highlighting its track record of success. The firm has recovered significant sums for investors, including over $438 million in 2019. The firm was ranked No. 1 by ISS Securities Class Action Services for the number of securities class action settlements in 2017 and has consistently ranked in the top 4 since 2013.

BNN's Perspective:

This lawsuit highlights the importance of transparency in the pharmaceutical industry and the potential financial consequences of failing to disclose critical information to investors and consumers. While the allegations are serious, it is important to remember that no class has been certified yet, and the outcome of the lawsuit remains uncertain. Investors should carefully consider their options and consult with legal counsel to determine the best course of action.

Keywords: RBGLY, Reckitt Benckiser, securities fraud, lawsuit, class action, Enfamil, NEC, Rosen Law Firm, investor rights, lead plaintiff, investor compensation, financial disclosure, legal claims, investor damages, securities class action

Full Story